Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of symptomatic severe aortic stenosis worldwide. This has largely been propelled by data from landmark randomized studies.1- 6 These studies have shown that TAVR is superior to medical therapy for the treatment of symptomatic severe aortic stenosis in patients at extreme risk in whom surgery is not an option.1,2 Compared with surgery, TAVR is noninferior or superior in high-risk patients and noninferior in intermediate-risk patients.3- 6 Randomized trials are now enrolling low-risk patients.
Stephen H. Little, Michael J. Reardon. Will Transcatheter Aortic Valve Replacement Echo Surgical Aortic Valve Replacement Durability?. JAMA Cardiol. 2017;2(11):1206–1207. doi:10.1001/jamacardio.2017.3307